KR100814214B1 - Immuno-stimulative composite comprising extract from bamboo sap - Google Patents
Immuno-stimulative composite comprising extract from bamboo sap Download PDFInfo
- Publication number
- KR100814214B1 KR100814214B1 KR1020060098710A KR20060098710A KR100814214B1 KR 100814214 B1 KR100814214 B1 KR 100814214B1 KR 1020060098710 A KR1020060098710 A KR 1020060098710A KR 20060098710 A KR20060098710 A KR 20060098710A KR 100814214 B1 KR100814214 B1 KR 100814214B1
- Authority
- KR
- South Korea
- Prior art keywords
- sap
- bamboo
- extract
- bamboo sap
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 24
- 235000017166 Bambusa arundinacea Nutrition 0.000 title claims description 75
- 235000017491 Bambusa tulda Nutrition 0.000 title claims description 75
- 241001330002 Bambuseae Species 0.000 title claims description 75
- 235000015334 Phyllostachys viridis Nutrition 0.000 title claims description 75
- 239000011425 bamboo Substances 0.000 title claims description 75
- 230000003308 immunostimulating effect Effects 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 239000002778 food additive Substances 0.000 claims abstract description 6
- 235000013373 food additive Nutrition 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 12
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 22
- 210000004027 cell Anatomy 0.000 abstract description 12
- 210000002540 macrophage Anatomy 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 241000745988 Phyllostachys Species 0.000 abstract description 4
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 230000002147 killing effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 2
- 239000011149 active material Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000011278 mitosis Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 13
- 230000006698 induction Effects 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 210000000822 natural killer cell Anatomy 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 7
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 6
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 235000018185 Betula X alpestris Nutrition 0.000 description 3
- 235000018212 Betula X uliginosa Nutrition 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000002766 immunoenhancing effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000208140 Acer Species 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229940124600 folk medicine Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 235000021579 juice concentrates Nutrition 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
도1은 대나무 수액의 추출물에 의한 림프구 증식 활성을 나타내는 그래프,1 is a graph showing the lymphocyte proliferation activity by the extract of bamboo sap,
도2는 대나무 수액 추출물의 싸이토카인 IL-2의 유도능력을 나타내는 그래프,Figure 2 is a graph showing the induction capacity of cytokine IL-2 of bamboo sap extract,
도3은 대나무 수액 추출물의 싸이토카인 IL-4의 유도능력을 나타내는 그래프,Figure 3 is a graph showing the induction capacity of cytokine IL-4 of bamboo sap extract,
도4는 대나무 수액 추출물의 싸이토카인 INF-r의 유도능력을 나타내는 그래프,Figure 4 is a graph showing the induction capacity of the cytokine INF-r of bamboo sap extract,
도5는 대나무 수액 추출물의 대식세포의 유도성 일산화 질소 신타아제의 유도능력(iNOS)을 나타내는 그래프,5 is a graph showing the induction capacity (iNOS) of inducible nitric oxide synthase of macrophages of bamboo sap extract,
도6은 대나무 수액 추출물의 대식세포의 증식을 유도하는 것을 나타내는 그래프이다.6 is a graph showing the induction of the proliferation of macrophages of bamboo sap extract.
본 발명은 대나무 수액의 추출물을 유효성분으로 함유하는 면역증강용 조성 물에 관한 것으로, 보다 상세하게는 상기 대나무 수액의 동결 건조물을 유효성분으로 함유하는 면역증강용 조성물과, 이를 함유하는 기능성 건강식품 또는 식품첨가제 및 약제조성물에 관한 것이다.The present invention relates to an immune enhancing composition containing an extract of bamboo sap as an active ingredient, and more particularly, an immune enhancing composition containing the freeze-dried product of the bamboo sap as an active ingredient, and a functional health food containing the same. Or it relates to food additives and pharmaceutical compositions.
대나무(Phyllostachys)는 화본과(Gramnineae)식물로서, 전 세계에 1,250여종이 있는 것으로 알려져 있고, 우리나라에서는 오래전부터 대나무가 많이 재배되어 왔는데 자생하고 있는 대나무의 종류는 13종이며, 대부분 전라남북도와 경남북도의 지역에 분포되어 있고, 강원도와 충청남도의 해안지방 그리고 제주도에 일부 분포하고 있다. Bamboo (Phyllostachys) is a plant native to Gramineae, and it is known that there are more than 1,250 species in the world. In Korea, bamboo has been cultivated for a long time. There are 13 kinds of bamboo grown in Korea. It is distributed in the area of, and is partly distributed in coastal areas of Gangwon-do and Chungcheongnam-do and Jeju-do.
예로부터 대나무는 고혈압, 발한, 중풍 등의 치료를 위한 민간약으로 활용이 되어 왔으며 방부 작용으로 하는 것으로도 알려져 있고, 그 수액보다는 줄기, 표피, 죽순 및 죽실 등이 질병 치료제로 이용되어져 왔으나 최근에는 고로쇠나무와 같이 수액을 채취하여 음용하고 있다. Since ancient times, bamboo has been used as a folk medicine for the treatment of hypertension, sweating, stroke, etc. It is also known as an antiseptic effect, and stem, epidermis, bamboo shoots and bamboo thread have been used as a medicine for treating diseases, but recently, Like sap, sap is collected and drinking.
이러한 대나무에 대한 연구중 대나무잎의 항미생물 활성에 대한 연구가 많이진행되어 있으나 대나무 수액에 대한 연구는 수액의 채취량과 채취 방법, 약수로의 이용 가능성에 대한 연구 정도만 행해지고 있다.While many studies have been conducted on the antimicrobial activity of bamboo leaves, research on bamboo sap has only been conducted on the sampling amount, the sampling method, and the availability of the distilled water.
수액이란 도관이나 사부를 통해 유동하는 액체로서 무기염, 질소화합물, 탄수화물, 효소, 식물호르몬 등이 용해되어 있는 비교적 묽은 용액이며, 수액의 조성은 물이 99.3%, 고형분은 0.7%에 불과하지만 보통의 물과는 엄청나게 다른 ‘물의 차별화’를 나타내고 있다. A sap is a liquid that flows through conduits or dead ends and is a relatively dilute solution in which inorganic salts, nitrogen compounds, carbohydrates, enzymes, and plant hormones are dissolved. The sap is composed of 99.3% water and 0.7% solids, but usually 'Water differentiation' is very different from water.
식물의 수액을 건강음료로 마시는 풍습은 소련, 중국, 일본에서는 오랜 역사 를 가지고 있으며 민간약으로 이뇨, 변비, 위장병, 고혈압, 혈당조절, 신경통 등에 효험이 있다고 하여 이들 수액의 성분에 관심이 높다. 수액을 산업화한 나라들의 경우 캐나다와 미국에서는 당단풍나무 수액을 가공하여 설탕 또는 시럽을 제조하며 일본 북해도에서는 자작나무 수액을 채취하여 건강음료로 판매하고 있다.The custom of drinking plant sap as a healthy drink has a long history in the Soviet Union, China, and Japan. It is a folk medicine that is effective in diuresis, constipation, gastrointestinal diseases, high blood pressure, blood sugar control, neuralgia, etc. In industrialized countries, sap maple syrup is processed in Canada and the United States to produce sugar or syrup, and birch sap is collected and sold as healthy drinks in Hokkaido, Japan.
대나무 수액은 고로쇠나무나 자작나무에 비해 더 많은 양의 수액을 채취할 수 있으며 당분과 무기성분의 함량이 특히 많아 전위, 이뇨, 신경 안정 및 심장질환의 발생 억제, 노폐물 제거 등에 효능이 있는 것으로 알려져 있으며, 타종에서 채취되는 수액과 비교하여 당과 무기성분의 함량이 높아 음용수로서의 가치가 높으으면서 항미생물의 활성이 큰 것으로 나타나 천연항균 물질로서의 이용 가능성도 보인다.Bamboo sap can collect more sap than cypress and birch, and it is known to be effective in dislocation, diuresis, nerve stabilization and suppression of heart disease, and elimination of waste products due to its high content of sugar and inorganic components. In addition, compared to the sap collected from other species, the content of sugar and inorganic components is high, the value of drinking water is high, and antimicrobial activity is shown to be great, so it can be used as a natural antibacterial substance.
우리나라에서는 지금까지 주로 대나무 자체의 가공기술, 즉 죽세공예기술의 개발에 대한 연구가 어느 정도 수행된 바 있으나 대나무 자원의 약리 효능이나 기능성을 이용한 기술개발은 거의 없었고 최근에 일부 학자들에 의해 대나무 추출액에 대한 항미생물의 활성에 관한 연구가 진행되고 있는 수준이다.In Korea, some studies have been conducted on the development of bamboo processing technology, that is, bamboo arts and crafts technology. Until now, however, there has been little development of technology using pharmacological efficacy or functionality of bamboo resources. The research on the activity of antimicrobial activity against is ongoing.
그리고, 국외에서의 대나무 자원에 대한 연구는 중국과 일본에서 일부 수행된 바 있고, 특히 중국의 경우 대나무 자원을 다양하게 이용해오고 있으나 주로 대나무를 이용한 건축자재 등의 산업화에 주력하고 있으며 대나무를 기능성 식품소재로 이용하는 기술은 아직까지 초보적인 단계에 있으며, 현재로서는 ‘죽건’이라는 대나무 음료를 개발하여 유통시키고 있는 실정이고 죽엽 추출물을 조제하여 쌀에 코팅한 ‘죽향미’도 개발된 바 있다.In addition, some research on bamboo resources in foreign countries has been conducted in China and Japan. Especially, in China, bamboo resources have been used in various ways, but mainly focus on industrialization of building materials using bamboo, and bamboo is a functional food. The technology used as a material is still in its infancy, and at present it is a state of developing and distributing bamboo beverages called 'jukgun' and 'juk flavor' coated with rice by preparing bamboo leaf extract has also been developed.
이처럼, 고로쇠수액, 단풍나무수액, 자작나무수액 등은 약리효과에 대한 여러 가지 연구가 진행된 바 있으나, 대나무 수액에 대한 연구는 많이 되어 있지 않고 특히, 그 약리효과에 대해서는 아직 보고된 바가 없다.As such, gorgo sap, maple sap, birch sap, etc. have been studied variously on the pharmacological effect, but the research on the bamboo sap has not been much, especially the pharmacological effect has not been reported yet.
본 발명은 대나무 수액의 동결 건조물을 유효성분으로 포함하는 면역증강용 조성물과 이를 함유한 기능성 건강식품 또는 식품첨가제 및 약제조성물을 제공하는 데에 그 목적이 있다.An object of the present invention is to provide a composition for immuno-enhancement comprising a freeze-dried product of bamboo sap as an active ingredient, and a functional health food or food additive and pharmaceutical composition containing the same.
상기한 목적을 달성하기 위하여 본 발명은 대나무 수액의 동결건조물을 함유한 실험군과 상기 추출물을 함유하지 않은 대조군으로 유사분열물질의 활성, 생리활성물질의 유도능, 생체내 급성독성시험, 유도성 일산화질소 신타아제 유전자 발현 및 NO 생성능, 자연살해세포 활성화 정도에 따른 면역증강 작용을 입증하여 대나무 수액의 동결건조물을 유효성분으로 하는 면역증강용 조성물과, 이를 함유한 기능성 건강식품 또는 식품첨가제 및 약제조성물을 제공하게 된다.In order to achieve the above object, the present invention is the experimental group containing the lyophilized bamboo sap and the control group does not contain the extract activity of the mitotic substance, the inducibility of the bioactive substance, in vivo acute toxicity test, inducible monoxide Immune synthetase gene expression, NO production ability, and natural immune cell activation, and proved the immune enhancing effect of the lyophilized composition of bamboo sap as an active ingredient, functional health food or food additives and pharmaceutical compositions containing the same Will be provided.
이하에서는 첨부된 도면을 참조하여 본 발명의 바람직한 실시예를 상세히 설명하기로 한다.Hereinafter, with reference to the accompanying drawings will be described a preferred embodiment of the present invention;
도1은 대나무 수액의 추출물에 의한 림프구 증식 활성을 나타내는 그래프이고, 도2는 대나무 수액 추출물의 싸이토카인 IL-2의 유도능력을 나타내는 그래프이며, 도3은 대나무 수액 추출물의 싸이토카인 IL-4의 유도능력을 나타내는 그래프이고, 도4는 대나무 수액 추출물의 싸이토카인 INF-r의 유도능력을 나타내는 그래프 이며, 도5는 대나무 수액 추출물의 대식세포의 유도성 일산화 질소 신타아제의 유도능력(iNOS)을 나타내는 그래프이고, 도6은 대나무 수액 추출물의 대식세포의 증식을 유도하는 것을 나타내는 그래프이다.1 is a graph showing the lymphocyte proliferation activity by the extract of the bamboo sap, Figure 2 is a graph showing the induction ability of the cytokine IL-2 of bamboo sap extract, Figure 3 is the induction capacity of the cytokine IL-4 of bamboo sap extract 4 is a graph showing the induction capacity of the cytokine INF-r of the bamboo sap extract, Figure 5 is a graph showing the induction capacity (iNOS) of the induced nitric oxide synthase of macrophages of the bamboo sap extract , Figure 6 is a graph showing inducing the proliferation of macrophages of bamboo sap extract.
실시예 1; 대나무 수액의 동결건조분말 제조Example 1; Lyophilized Powder Preparation of Bamboo Sap
본 발명의 재료인 대나무 수액의 채취는 5~6월에 채취하였으며, 채취한 대나무 수액은 동결 건조를 통해 분말화한 후 -20℃의 온도에서 사용 전까지 보관하였고, 동물세포에 처리 전 500mg/ml의 농도로 녹여, 망크기(pore size)가 0.22㎛인 멤브레인 필터(membrane filter)로 여과시켜 -20℃에 보관하고 실험에 이용하였다.The harvesting of bamboo sap, the material of the present invention, was collected in May-June, and the collected bamboo sap was powdered by freeze-drying and stored at -20 ° C until use, and 500 mg / ml before treatment in animal cells. It was dissolved at a concentration of and filtered through a membrane filter (pore size) of 0.22㎛ (membrane filter) and stored at -20 ℃ was used for the experiment.
비교예 1; 대나무 수액이 면역관련세포의 유사분열물질(mitogen)에 미치는 영향Comparative Example 1; Effect of Bamboo Sap on Mitogen in Immune-Related Cells
5주령의 Balb/c 마우스로부터 비장을 적출하고, 비장세포(splenocytes)의 수가 2×105 /100㎕의 밀도로 조정하여 각 웰(well)에 넣고 대나무 수액을 각각 200㎍/㎖, 100㎍/㎖, 50㎍/㎖ 및 10㎍/㎖를 첨가하였다.Harvesting the spleen from the Balb / c mice of 5 weeks of age, and the number of spleen cells (splenocytes) adjusted to a density of 2 × 10 5 / 100㎕ to put into each well (well) to each
양성 대조군으로 T-세포 및 B-세포의 유사분열 물질인 콘카바날린-A(Concavanallin-A;이하 Con-A라 약칭함)와 지질 다당류(Lipopolysaccharide;이하 LPS라 약칭함)의 최종농도가 각각 0.5㎍/㎖ 및 5㎍/㎖가 되도록 조정하여 각 웰(well)에 처리하고, 실험군과 대조군을 37℃, 5% CO2 조건 하에서 3일간 배양하고 시료에 의한 림프구의 증식활성(proliferation assay)을 조사하였다.As a positive control, the final concentrations of concavanallin-A (hereinafter referred to as Con-A) and lipopolysaccharide (hereinafter referred to as LPS), which are mitotic substances of T-cell and B-cell, respectively Each well was adjusted to 0.5 μg / ml and 5 μg / ml, and the experimental and control groups were incubated for 3 days at 37 ° C. and 5% CO 2, and the proliferation assay of the lymphocytes by the sample was observed. Was investigated.
림프구(Lymphocyte)의 증식활성(proliferation activity)은 MTT[3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]법으로 수행하였으며, 상기 MTT법은 5㎎/㎖의 농도로 조정된 MTT시약을 각 웰(well)에 50㎕첨가하고 6시간 배양하여 MTT시약과 살아있는 세포가 생산하는 미토콘드리아 탈수소효소(mitochondria dehydrogense)와 반응하여 생성된 비수용성의 진청색 포마잔(formazan)의 양을 570㎚에서 흡광도를 측정함으로써 림프구의 증식활성을 측정하였다. Lymphocyte proliferation activity was performed by MTT [3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide] method, and the MTT method was 5 mg / ml. 50 μl of the concentration-adjusted MTT reagent was added to each well and incubated for 6 hours to react with the mitochondria dehydrogense produced by the MTT reagent and living cells, resulting in non-aqueous dark blue formazan. The proliferative activity of lymphocytes was measured by measuring the absorbance at 570 nm.
본 비교예 1의 결과는 도 1에 나타낸 바와 같이 대나무 수액 동결 건조물이 시료 무처리 대조군에 비하여 높은 비장세포의 증식활성을 나타내었다.As shown in FIG. 1, the result of Comparative Example 1 showed that the sap freeze-dried product showed higher proliferation activity of splenocytes compared to the sample-free control group.
본 비교예의 결과로서 본 발명이 B-세포 또는 T-세포 중 어떤 종류의 면역세포를 활성화시키는지 확인하지 못하였으나 비특이적으로 비장세포를 직접 자극하는 활성작용이 있음을 확인하였다. As a result of this comparative example, it was not confirmed whether the present invention activates any kind of immune cells among B-cells or T-cells, but it was confirmed that there is an activating activity that directly stimulates splenocytes nonspecifically.
또한, 유사한 실험으로 5주령의 Balb/c 3% 티오글리콜레이트(thioglycollate) 1㎖를 복강투여하고 3일 후에 마우스의 복강세포(Perotoneal Exaudative Cell; 이하 PEC라 약칭함)를 멸균적으로 수집하여 24웰 플레이트(48well plate)의 각 웰(well)에 1×106/㎖의 농도로 도말한 후, 2시간 정도 배양하고 PBS로 각 웰(well)을 세척하여 플레이트에 부착된 대식세포(macrophage)를 회수하였다. In a similar experiment, 1 ml of 5 weeks old Balb / c 3% thioglycollate was intraperitoneally administered and 3 days later, sterile cells of mice were sterilely collected (24). Each well of the well plate (48 well plate) is plated at a concentration of 1 × 10 6 / ㎖, incubated for about 2 hours and washed each well with PBS (macrophage attached to the plate) Was recovered.
INF-r와 동시에 대나무 수액을 각각 200㎍/㎖, 100㎍/㎖, 50㎍/㎖ 및 10㎍/㎖ 로 처리하여 iNOS 및 NO의 생성량을 정량하였다. The amount of iNOS and NO was quantified by treating bamboo sap with INF-r at 200 µg / ml, 100 µg / ml, 50 µg / ml and 10 µg / ml respectively.
실험 수행 결과 대나무 수액 단독 처리군에서는 NO 및 iNOS의 생성 변화를 관찰할 수 없었으나, INF-r와 동시 처리한 군에서는 시료의 농도에 의존하여 NO 및 iNOS의 값이 증가하는 것을 관찰할 수 있었다. As a result of the experiment, NO and iNOS production change could not be observed in the bamboo sap treatment group, but the increase of NO and iNOS value was observed in the group treated with INF-r depending on the concentration of the sample. .
본 비교예의 결과로 본 발명은 성숙된 면역담당세포가 효과적인 면역반응을 유도케 하는 세포반응성을 증진시키는 효과가 있으며, 외부의 항원에 노출되었을 경우 본 발명이 투여된 생체는 비특이적 면역 반응 뿐만 아니라, 항원 특이적인 면역반응을 위한 작동세포의 수를 증가시키므로 외부로부터의 항원에 대하여 효과적인 방어효과를 유도할 수 있는 것으로 확인하였다.As a result of this comparative example, the present invention has the effect of enhancing the cellular reactivity of the mature immune cells to induce an effective immune response, when exposed to an external antigen, the living body to which the present invention is administered is not only a nonspecific immune response, Since the number of effector cells for the antigen-specific immune response is increased, it was confirmed that it can induce an effective protective effect against the antigen from the outside.
비교예 2Comparative Example 2
1. 대나무 수액의 생리활성물질(cytokine)의 유도 1. Induction of Cytokine from Bamboo Sap
대나무 수액이 면역관련세포의 유사분열물질(mitogen)에 미치는 영향Effect of Bamboo Sap on Mitogen in Immune-Related Cells
5주령의 Balb/c 마우스로부터 비장을 적출하고, 비장세포(splenocytes)의 수를 2×106 /500㎕의 밀도로 조정하여 각 웰(well)에 넣고 대나무 수액을 각각 200㎍/㎖, 100㎍/㎖, 50㎍/㎖ 및 10㎍/㎖를 첨가하여 24시간 동안 동시배양 하였다.Harvesting the spleen from the Balb / c mice of 5 weeks of age, and by adjusting the number of spleen cells (splenocytes) at a density of 2 × 10 6 / 500㎕ put into each well (well) to each
또한, 양성 대조군으로 Con A의 최종농도를 0.5㎍/㎖가 되도록 조정하여 웰(well)에 처리하고 24시간 동안 배양하였고, 배양완료 후에 상등액만을 회수하고 상등액에 유도 분비된 IL-2, IL-4, IL-10, INF-r 등 여러 가지 생리활성물질(cytokine)을 각 싸이토카인 킷(cytokine kit)을 이용하여 측정하였다.In addition, the final concentration of Con A was adjusted to be 0.5 μg / ml as a positive control, treated in wells and incubated for 24 hours. After the incubation, only the supernatant was recovered and the secreted induction into the supernatant was IL-2 and IL-. Various cytokines such as 4, IL-10, INF-r, etc. were measured using each cytokine kit.
본 비교예 2의 결과는 도 2 내지 도 4에 나타낸 바와 같이 대나무 수액은 마 우스의 췌장 세포를 직접 활성화시켜 IL-2, IL-4, IL-10, INF-r 등의 면역 관련 싸이토카인을 유도하는 면역자극효과가 있음을 확인하였다.As shown in FIGS. 2 to 4, bamboo sap directly activates mouse pancreatic cells to induce immune-related cytokines such as IL-2, IL-4, IL-10, and INF-r. It was confirmed that the immune stimulating effect.
본 발명은 싸이토카인의 종류, 대나무 수액의 농도에 따라 싸이토카인을 유도하는 정도가 달랐으나, 농도에 의존하여 싸이토카인 유도체(cytokine inducer)로의 활성이 있음을 확인하였다.In the present invention, the degree of inducing cytokine was different depending on the type of cytokine and the concentration of the sap of bamboo, but it was confirmed that there is activity as a cytokine derivative (cytokine inducer) depending on the concentration.
2. 대나무 수액의 생체내 급성독성 시험2. In vivo acute toxicity test of bamboo sap
25g의 웅성 Balb/c 마우스에 대나무 수액을 구강 투여를 통해 마우스당 2,000㎍/kg, 500㎍/kg 및 100㎍/kg을 2일 간격으로 계속 투여 하였으며, 15일간 마우스의 생존율 및 체중을 조사하였다.25 g of male Balb / c mice were orally administered with 2,000 sag / kg, 500 μg / kg and 100 μg / kg per mouse via oral administration, and the survival and body weight of the mice were examined for 15 days. .
본 비교예에 의한 대나무 수액을 투여한 마우스의 생존율 및 체중 그리고 간 수치를 각각 다음의 표 1 내지 표 3에 나타내었다.Survival, body weight and liver values of the mice administered bamboo sap according to the comparative example are shown in Tables 1 to 3, respectively.
표 1. 대나무수액을 투여한 마우스의 생존율Table 1. Survival rate of mice administered bamboo sap
표 2. 대나무수액을 투여한 마우스의 체중변화Table 2. Changes in body weight of mice administered bamboo sap
표 3. 대나무 수액을 투여한 마우스의 간수치Table 3. Liver Numbers of Mice Administered with Bamboo Sap
상기 표 1에 나타낸 바와 같이 대나무 수액은 투여량에 관계없이 마우스의 생존율에 영향을 미치지 않는 것으로 나타났으며, 이와 같은 결과는 상기 대나무 수액이 생체의 생존에 영향을 미치지 않음을 증명하였다.As shown in Table 1, the bamboo sap did not appear to affect the survival rate of the mice regardless of the dose, this result proved that the bamboo sap does not affect the survival of the living body.
또한, 상기 표 2에 나타낸 바와 같이 대나무 수액을 처리한 실험군은 시료 무처리 대조군과 유사한 체중증가를 나타냄으로써 대나무 수액은 생체의 조직적 손상을 유도하지 않는 결과를 나타내었다.In addition, as shown in Table 2, the experimental group treated with the bamboo sap showed a similar weight gain as the sample untreated control group, indicating that the bamboo sap did not induce tissue damage of the living body.
그리고, 상기 표 3에서 보는 바와 같이 대나무 수액 처리군의 간수치를 조사한 결과 정상군과 유의성 있는 차이를 보이지 않아 아무런 간손상도 유발하지 않은 것을 관찰할 수 있었다.And, as shown in Table 3 above, as a result of examining the liver digits of the bamboo sap treatment group did not show a significant difference with the normal group, it could be observed that did not cause any liver damage.
3. 자연살해세포(Natural Killer cell; 이하 NK-세포라 약칭함)활성화에 미치는 효과 측정3. Determination of the effect on the activation of natural killer cells (abbreviated as NK-cells)
22g의 웅성 Balb/c 마우스에 대나무 수액을 각각 200㎍/kg, 50㎍/kg 및 10㎍/kg을 7일 동안 구강 투여하고 7일 후 마우스의 비장을 멸균적으로 수획한 비장세포와 NK-세포에 민감세포주인 YAC-1을 동시에 6시간 배양하였다. 22 g of male Balb / c mice were orally administered 200 μg / kg, 50 μg / kg and 10 μg / kg of bamboo sap respectively for 7 days, and after 7 days the spleen cells and NK- The cells were incubated for 6 hours with YAC-1, a sensitive cell line.
배양한 비장세포를 효과 기주세포(Effector cell; E)로 사용하고, 배양한 YAC-1을 표적세포(Target cell;T)로 사용하였다. Cultured splenocytes were used as effector cells (E) and cultured YAC-1 was used as target cells (T).
NK-세포에 의한 살해효과는 자연살해세포의 세포독성 분석법인 크롬-유리법( 51 Cr-release법)을 이용하여 상기 표적세포와 효과기세포를 1,400rpm으로 1분간 원심분리하고 37℃에서 4시간 배양하였다. The killing effect by NK-cells was centrifuged at 1,400 rpm for 1 minute using chromium-free method (51 Cr-release method), which is a cytotoxicity assay of natural killer cells, and 4 hours at 37 ° C. Incubated.
스카트론(Skatron)기기를 사용하여 상층액을 회수하고 g-계수기로 계수하고 세포독성 프로그램으로 실험적 유리량(experimental release), 자연적 유리량(spont aneous release), 최대 유리량(maximum release)을 측정하여 이하의 식으로 NK-세포의 활성을 산출하였다. Supernatant was recovered using a Skatron instrument, counted with a g-counter, and cytotoxic programs measured for experimental release, spontaneous release, and maximum release. In this way, the activity of NK-cells was calculated.
NK-세포의 활성(%)=[실험적 유리량(experimental release)-자연적 유리량(spontaneous release)/최대 유리량(maximum release)-자연적 유리량(spontaneous release)]×100NK-cell activity (%) = [experimental release-spontaneous release / maximum release-spontaneous release] × 100
표 4. 대나무수액이 자연살해 세포에 미치는 영향Table 4. Effect of Bamboo Sap on Natural Killing Cells
상기 표 4에 나타낸 바와 같이 대나무 수액이 미치는 NK-세포 활성은 E/T 비율과 대나무 수액에 비례함을 확인하였다.As shown in Table 4, it was confirmed that the NK-cell activity of bamboo sap is proportional to the E / T ratio and bamboo sap.
대나무 수액을 투여한 실험군과 대조군을 비교하였을 때 대나무 수액 200㎍을 투여한 마우스의 비장세포는 대조군 마우스에 비하여 약 4배 정도의 NK-세포 활성을 나타내었으며 대나무 수액 10㎍을 투여한 경우도 대조군에 비하여 유효한 활성을 나타냈다.Compared with the control group administered with bamboo sap and the control group, the splenocytes of mice treated with 200 μg of bamboo sap showed about four-fold NK-cell activity compared to the control mice. Compared to the effective activity was shown.
상기와 같이 대나무 수액으로 인한 림프구 증식활성, 생리활성물질의 유도능력, 생체내 독성시험, iNOS 및 NO의 유도능력 , 자연살해세포 활성화 등에 유리하게 작용함을 입증하였다.As described above, it was proved to be beneficial for lymphocyte proliferation activity due to the sap of bamboo, the ability to induce physiologically active substances, in vivo toxicity test, the ability to induce iNOS and NO, activation of natural killer cells.
상기 대나무 수액을 식품 또는 약제의 조성물로 사용할 수 있으며 상기 추출물을 동결건조 또는 농축액의 형태로 식품 또는 약제의 조성물로 사용할 수 있다.The bamboo sap may be used as a composition of food or medicament, and the extract may be used as a composition of food or medicament in the form of lyophilization or concentrate.
하기에서 상기 조성물의 제제예를 구체적으로 설명하기로 한다.Hereinafter, the preparation examples of the composition will be described in detail.
제제예; 건강기능성음료의 제조Formulation examples; Preparation of Health Functional Drink
실시예; 대나무수액 1~15중량%Example; Bamboo sap 1-15% by weight
대나무수액의 농축액 1~2중량% 1 ~ 2% by weight of bamboo sap
액상과당 1~10중량% 1 to 10 wt% of liquid fructose
구연산 0.01~1중량% Citric acid 0.01 ~ 1% by weight
대나무추출액 0.05~0.5중량% Bamboo extract 0.05 ~ 0.5% by weight
베타인 0.01~1.0중량% Betaine 0.01 ~ 1.0 wt%
식이섬유 0.1~1.0중량% Dietary Fiber 0.1 ~ 1.0% by weight
과즙농축액 0.1~2.0 중량% Juice concentrate 0.1 ~ 2.0 wt%
정제수를 가하여 전체 800ml Add 800 ml of purified water
예컨대, 본 발명의 대나무 수액의 추출물을 이용한 건강기능성음료는 통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 80℃에서 30분정도 살균한 후 용기에 넣어 밀봉하여 2차 저온살균시킨 후 유리병 등 소포장용기에 포장하여 건강기능성음료를 제조하였다.For example, the health functional beverage using the extract of the bamboo sap of the present invention is mixed with the above components according to the conventional health beverage manufacturing method, sterilized for about 30 minutes at 80 ℃ and sealed in a container to secondary pasteurization After packaging in a small packaging container such as glass bottles to prepare a health functional beverage.
이와 같이, 본 발명의 상세한 설명에서는 구체적인 실시예에 관해 설명하였으나, 이는 본 발명의 범주에서 벗어나지 않는 한도내에서 여러가지 변형이 가능함은 물론이다.As described above, in the detailed description of the present invention, specific embodiments have been described, but various modifications may be made without departing from the scope of the present invention.
그러므로, 본 발명의 실질적인 범위는 상술된 실시예에 의해 한정되어져서는 안되며, 후술하는 청구범위 뿐만 아니라 청구범위와 균등한 구성에 의해 정해져야 함은 당연하다.Therefore, the substantial scope of the present invention should not be limited by the above-described embodiment, but should be defined by the same structure as the claims as well as the claims described below.
이상과 같이 구성되는 본 발명은 대나무 수액을 유효성분으로 하는 면역증강용 조성물을 추출함으로써 상기 면역증강용 조성물의 투여는 종양세포에 대해 직접적으로 대항하는 대식세포 및 자연살해세포의 활성을 높이고, 유사분열 물질 및 생리활성물질을 증가시켜 종양을 비롯한 외부 항원에 대한 항체 생산을 증진시키는 효과가 있다.The present invention is configured as described above by extracting the composition for immuno-enhancing bamboo sap as an active ingredient, the administration of the immuno-enhancing composition increases the activity of macrophages and natural killer cells directly against tumor cells, and similar Increasing cleavage and bioactive substances has the effect of enhancing the production of antibodies to foreign antigens, including tumors.
또한, 본 발명은 상기 대나무 수액을 식품 또는 식품첨가제 및 약제에 조성물로 사용함으로써 일상의 식생활로 면역과 관련된 질환을 예방하는 효과가 있다.In addition, the present invention has the effect of preventing diseases associated with immunity to daily diet by using the bamboo sap as a composition in food or food additives and pharmaceuticals.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060098710A KR100814214B1 (en) | 2006-10-11 | 2006-10-11 | Immuno-stimulative composite comprising extract from bamboo sap |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060098710A KR100814214B1 (en) | 2006-10-11 | 2006-10-11 | Immuno-stimulative composite comprising extract from bamboo sap |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100814214B1 true KR100814214B1 (en) | 2008-03-17 |
Family
ID=39410731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060098710A KR100814214B1 (en) | 2006-10-11 | 2006-10-11 | Immuno-stimulative composite comprising extract from bamboo sap |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100814214B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102657275B1 (en) * | 2023-11-03 | 2024-04-15 | 주식회사 비오맘 | Food composition for improving diet and bowel movement with improved intake and absorption power |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006022739A (en) * | 2004-07-08 | 2006-01-26 | Toyota Motor Corp | Exhaust emission control system for internal combustion engine |
-
2006
- 2006-10-11 KR KR1020060098710A patent/KR100814214B1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006022739A (en) * | 2004-07-08 | 2006-01-26 | Toyota Motor Corp | Exhaust emission control system for internal combustion engine |
Non-Patent Citations (1)
Title |
---|
대한한방내과학회지 18(2), 27-39 (1997) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102657275B1 (en) * | 2023-11-03 | 2024-04-15 | 주식회사 비오맘 | Food composition for improving diet and bowel movement with improved intake and absorption power |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102178926B1 (en) | A composition for reinforcing immune function and anti-fatigue comprising fermented placenta and its use | |
KR101734979B1 (en) | Composition for preventing and treating cancer, and enhancing the immune action | |
KR101184349B1 (en) | Composition for enhancement of immune function and improvement of hematopoiesis which comprises antler fermented with Bacillus subtilis KCTC 11454BP as an active ingredient, and a preparation method thereof | |
KR20180090198A (en) | Composition comprising the extract of Molokia leaf for immune activity | |
KR101356611B1 (en) | Vinegar of fermented pepper leaf with increased AGI activity and method for preparing the same | |
KR102315959B1 (en) | A composition for reinforcing immune function comprising the extract of oat sprout | |
KR100814214B1 (en) | Immuno-stimulative composite comprising extract from bamboo sap | |
KR101704123B1 (en) | Method for seperating bee venom containing active amines and food composition thereof | |
KR102368892B1 (en) | A composition for anti-inflammatory comprising extracts of single leaf cremastra and sigesbeckia glabrescens makino | |
KR101626642B1 (en) | Composition comprising fermented extract of trifoliate orange for improving diabetes | |
KR20210003994A (en) | Polysaccharide fraction isolated from Nelumbo nucifera leaf with immune-enhancing activity and method for producing the same | |
KR101604347B1 (en) | Pharmaceutical composition comprising an extract or a fraction of Pistacia weinmannifolia J. Poiss. Ex Franch for preventing or treating inflammatory-related diseases | |
KR101113603B1 (en) | Extract composition of herbal mixture for improving liver fucntion and relieving hangover | |
KR20200065170A (en) | Composition for Prophylaxis and Treatment of Osteoporosis, Diabetes and Obesity Comprising Fermented Tremella fuciformis Berk. | |
KR102470155B1 (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
JP4327727B2 (en) | Composition for the treatment and immunity enhancement of myeloid leukemia containing hamcho extract | |
KR20210147247A (en) | A composition for immune enhancement comprising narrow-leaf erecta fig extract mixture | |
KR100510174B1 (en) | Composition for treating myeloid leukemia and increasing immunity comprising Salicornia herbacea extracts. | |
KR101488434B1 (en) | Immune-enhancing composition including inonotus obliquus extract | |
KR101184355B1 (en) | Composition for enhancement of immune function and improvement of hematopoiesis which comprises antler fermented with Cordyceps militaris KCTC 11455BP as an active ingredient, and a preparation method thereof | |
KR101715996B1 (en) | Composition for antidiabetic activity comprising dichloromethane or ethyl acetate fraction of Hizikia fusiformis extract as effective component | |
KR102691084B1 (en) | A composition for improving and preventing obesity comprising complex-fermented fruits of Cudrania tricuspidata and its preparation method | |
KR102093817B1 (en) | Polysaccharide fraction isolated from Nelumbo nucifera leaf with immune-enhancing activity and method for producing the same | |
KR102527252B1 (en) | A composition for improving immune comprising enzyme hydrolysate containing Rhodiola sachalinensis A. Bor | |
KR100657423B1 (en) | Pharmaceitical composition for immune improvement comprising protein extract, crude protein-polysaccharide extract of korean acanthopanax senticosus extract which were extracted korean acanthopanax senticosus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20120409 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20121226 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160318 Year of fee payment: 9 |
|
LAPS | Lapse due to unpaid annual fee |